JAK inhibitors don't increase risk of VTE in Atopic Dermatitis patients: JAMA

The use of JAK Inhibitors does not increase the risk of Venous thromboembolism in patients with Atopic Dermatitis as per a new study that was published in JAMA Network. 

There is not much evidence on the risk of venous thromboembolism (VTE) in patients with Atopic dermatitis (AD) under Janus kinase inhibitor treatment. Hence researchers conducted a study to find the association of AD with incident VTE and evaluate the risk of incident VTE among patients with AD who were receiving treatment with JAK inhibitors. Using keywords without any language or geographical restrictions, MEDLINE, Embase, Cochrane Library, and Web of Science databases were searched from the inception to February 5, 2022. Cohort studies that find the association of AD with incident VTE and randomized clinical trials (RCTs) that report VTE events in patients receiving JAK inhibitors were included. Of these only 0.7% of initially identified articles met the selection criteria. PRISMA guidelines were followed, and the risk of bias was assessed in included cohort studies, and RCTs by the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool 2, respectively. Pooled hazard ratio (HR) and risk difference for incident VTE was calculated using the random-effects model meta-analysis.